 Believe it or not, Humira still drives headlines for AbbVie (NYSE: ABBV), despite contributing little to the company's growth. Once AbbVie's biggest... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ |
Good MorningU.S. stocks were mixed Monday as the Dow advanced while the Nasdaq fell, with weakness in semiconductor-related names including Micron and Seagate. Amazon gained, while Lumentum and Marvell Technology declined following Marvell's announcement of a $115 billion acquisition of Lumentum. Investors are also watching upcoming reports from Arm, The Trade Desk, NuScale and quantum-computing companies after steep October declines in the sector.
Falling oil prices provided a lift to airline shares, offering relief from fuel-cost pressure for carriers such as Delta and JetBlue. Energy stocks were weaker, however, with several oil producers and offshore drillers declining. Cheniere Energy reported a third-quarter earnings miss tied to higher costs, although revenue beat expectations and the company highlighted record cargo exports and higher guidance.
Earnings reactions remained selective. IDEXX Laboratories surged after beating third-quarter estimates and raising full-year guidance, while Krystal Biotech posted an earnings beat and 30% revenue growth but its shares slipped. Starbucks fell after missing revenue expectations amid declining sales tied largely to its China-business transition. Investors are also weighing renewed concerns around CoreWeave, while CrowdStrike expanded its AI-integration partnership with the company. Featured: $250,000, $2,500 a month: here's when it runs out (Ad) 
| Healthcare | |
Believe it or not, Humira still drives headlines for AbbVie (NYSE: ABBV), despite contributing little to the company's growth. Once AbbVie's biggest revenue driver, sales fell to a paltry $683 million in Q3 due to its long-feared patent cliff, a catalyst that has come and gone. The patent cliff was... Read the Full Story |
| From Our Partners | | Elon Musk may be quietly building a device that could rival the iPhone.
Government documents, new trademarks, and recent deals all point to a major upcoming launch from Musk.
See the evidence behind the next big move from one of tech's most closely watched innovators. | | See the evidence behind Elon Musk's next mega-launch now |
| Markets | |
As the latest earnings results from pharma giant Eli Lilly and Co. (NYSE: LLY) confirm, GLP-1 agonists are still a very big business. Despite changes to Medicare and a reimbursement program in China that could threaten to drag down prices and cut into margins, massive volume growth for some of the ... Read the Full Story |
| Healthcare | |
American mortgage rates have done something unusual to the housing conversation: they’ve made buying feel like a lifestyle decision again instead of an investment one. Home sales slow, headlines fixate on the rate print, and property quietly drops off a lot of portfolios.
Ronan McMahon of Real Esta... Read the Full Story |
| From Our Partners | | In 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again until age 85.
In 2008, one bad year wiped out more than half the savings of those aged 56 to 65. Today, the national debt stands at 38.86 trillion dollars, far higher than in 1929.
See where your retirement stands with a free Retirement Protection Kit. | | Get your free Retirement Protection Kit before November 3 |
| Technology | |
The AI trade has taken a heavy beating lately, and few corners have been spared. Chip stocks, memory names, and neocloud providers have all sold off hard. Intel (NASDAQ: INTC) has fallen about 55% from its 52-week high, Alphabet (NASDAQ: GOOGL) nearly 30%, and Nebius (NASDAQ: NBIS) about 50%. Even ... Read the Full Story |
| Industrials | |
When it comes to flashy stocks, investors have many options—but environmental services companies will likely never be on the list. Nonetheless, companies providing essential services to businesses and communities have remarkable stability and staying power in the face of inflation and other macroec... Read the Full Story |
| From Our Partners | | Small-cap moves rarely announce themselves. Street Ideas surfaces quiet setups with real momentum before they appear on mainstream radars.
With tomorrow's open approaching, three names are already showing early activity worth a closer look. Get the alerts that keep you ahead of the crowd. | | Join Street Ideas - Get Your Free Report Sent To Your Email |
| Healthcare | |
Investors just sold off a company for spending money on the one business that doubled.
Alphabet Inc. (NASDAQ: GOOGL) fell 12% after its third-quarter report, erasing more than $400 billion in market value. Google Cloud revenue grew 103% in that same quarter.
That’s the tension worth sitting with, b... Read the Full Story |
| Technology | |
Investors have hit tech stocks hard over the past few weeks. The Technology Select Sector SPDR Fund (NYSEARCA: XLK), a commonly used proxy for the sector’s performance, is down more than 7% in October. Fears around the AI buildout's sustainability and disappointing earnings reports from Big Tech ha... Read the Full Story |
| Technology | |
Strategy (NASDAQ: MSTR) recently reported a headline third-quarter net income approaching $19.5 billion, largely due to a fair-value adjustment on its digital asset treasury.
While a $21 billion paper profit grabs attention, underlying capital flows suggest a more calculated pivot. Strategy has te... Read the Full Story |
| Energy | |
Soaring gas and diesel prices have boosted the energy sector, and many refiners are posting record profits and all-time high stock prices.
Uranium is another energy source that’s nearing record prices, but it functions a bit differently than a typical commodity.
Uranium contracts aren’t traded on a... Read the Full Story |
| Consumer Discretionary | |
Royal Caribbean Cruises Ltd. (NYSE: RCL) and Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) both beat recent earnings expectations, leaning on a wave of last-minute bookings to deliver third-quarter beats.
Consumers are still spending on leisure travel, and cruise operators are capturing that dem... Read the Full Story |
| Tuesday's Early Bird Stock Of The Day Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. | Should I Buy Eli Lilly and Company Stock? LLY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Tuesday, November 03, 2026 at 1:05 AM.
Eli Lilly and Company Bull Case -
Eli Lilly and Company recently reported third-quarter earnings that significantly exceeded expectations, with actual earnings per share of $7.48 beating the consensus estimate of $5.71, while revenue of $24.40 billion also surpassed the projected $22.58 billion, demonstrating strong fundamental performance.
-
The company has raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion, indicating management confidence in sustained growth driven by high demand for its GLP-1 products like Mounjaro and Zepbound.
-
Analyst sentiment remains positive, with Cantor Fitzgerald recently raising its price target to $1,600.00 and maintaining an overweight rating, suggesting potential upside from the current stock price of $1,412.06.
-
The stock has demonstrated strong momentum, trading near its 52-week high of $1,449.68, which reflects investor confidence in the company's market position and recent financial results.
-
Eli Lilly and Company maintains a low beta of 0.46, indicating that the stock is less volatile than the broader market, which may appeal to investors seeking stability in their portfolio.
Eli Lilly and Company Bear Case -
The company trades at a high price-to-earnings ratio of 40.91, which may limit upside potential if growth slows, as some analysts have noted signs of cooling revenue growth ahead.
-
Recent insider activity includes sales by executives such as Patrik Jonsson and Anat Hakim in August 2026, which some investors may interpret as a signal of reduced confidence in near-term stock performance.
-
Short interest has increased in recent months, with shares shorted rising to 6,960,837 as of October 2026, suggesting that some market participants are betting against the stock's future price movement.
-
The stock price has recently declined from its previous close of $1,417.54 to $1,412.06, indicating short-term selling pressure despite the recent earnings beat.
-
Some analysts have downgraded their ratings or expressed concerns about the sustainability of the current growth rate, noting that while margins remain solid, slowing revenue could impact future profitability.
| | View Today's Stock Pick |
|
| |
|
|
